Metronidazol Fresenius

Metronidazole, the active ingredient in Metronidazol Fresenius, is a nitroimidazole presented as an injectable solution for intravenous use. It is an antibiotic indicated for the treatment of anaerobic bacterial infections, intra‑abdominal infections, pelvic inflammatory disease, bacterial vaginosis, trichomoniasis, and as adjunct therapy for Clostridioides difficile infection in adult patients.

GNH USA supplies Metronidazol Fresenius as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide, with the product sourced from EU manufacturers and meeting European pharmacopoeia specifications, and adhering to stringent quality control procedures.

Metronidazole is an antibacterial agent used to treat infections caused by anaerobic bacteria and certain protozoa. - Anaerobic bacterial infections: eradicates susceptible anaerobes in tissues and body cavities. - Intra‑abdominal infections: resolves polymicrobial infections involving the peritoneum and abdominal organs. - Pelvic inflammatory disease: eliminates causative anaerobic organisms to improve pelvic health. - Bacterial vaginosis: restores normal vaginal flora by targeting Gardnerella and related anaerobes. - Trichomoniasis: kills Trichomonas vaginalis, relieving symptoms and preventing transmission.

Metronidazole may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Metallic taste: transient metallic sensation in the mouth. - Headache: occasional mild headache. - Diarrhea: loose stools that resolve after therapy. - Peripheral neuropathy (reversible): tingling or numbness in extremities with prolonged use.

Serious or Rare Side Effects: - Seizures: rare central nervous system events. - Severe allergic reaction: rash, itching, swelling, or anaphylaxis. - Hepatotoxicity: elevated liver enzymes or jaundice. - Blood dyscrasias: neutropenia, leukopenia, or thrombocytopenia. - Stevens‑Johnson syndrome/toxic epidermal necrolysis: severe skin reactions.

When using Metronidazol Fresenius, clinicians should observe several safety considerations to minimize risk. - Pregnancy: Category B, use only if benefit outweighs potential risk. - Alcohol interaction: avoid alcohol during and up to 48 hours after therapy to prevent disulfiram‑like reaction. - Renal impairment: adjust dosing in severe renal dysfunction. - Neuropathy monitoring: assess for peripheral neuropathy during prolonged treatment. - Liver disease: use cautiously in patients with hepatic impairment. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Metronidazol Fresenius can affect the activity of other medicines; notable interactions are grouped by clinical significance.

Major Interactions (Avoid): - Alcohol: concurrent intake may cause severe flushing, tachycardia, and hypotension. - Warfarin: increased anticoagulant effect, may require INR monitoring.

Moderate Interactions (Monitor Closely): - Lithium: may increase lithium levels, monitor serum concentration. - Cimetidine: can raise metronidazole plasma concentrations. - Phenobarbital and carbamazepine: may reduce metronidazole efficacy. - Oral contraceptives: possible reduction in effectiveness, advise additional contraceptive measures.